Innovative Medicines
for Rare Diseases
We focus on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases.
Orphan & Specialty Care Medicines in Switzerland
Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies.
Curatis holds exclusive distribution rights for 40+ products and aims to significantly increase this number. In addition, Curatis is securing distribution rights for drugs in major European markets: Germany, France, United Kingdom, Italy.
Specialty & Orphan Drugs
Specialty care drugs, orphan drugs, and antidotes
Market Access
Registration, pricing, and reimbursement services
Marketing & Sales
Targeted marketing and sales activities for specialised products
Early Access Programmes
Facilitating patient access before full market authorisation
Quality & Pharmacovigilance
State-of-the-art quality and pharmacovigilance know-how
Efficient Operations
Fast operational processes and communication with partners
Novel Medicines for Unmet Medical Needs
Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization.
Peritumoral Brain Edema
Compound: corticorelin
Oncology / Neurology
Severe Migraine with Aura Prevention
Neurology
Medication Overuse Headache
Neurology
Fibrotic or Inflammatory Orphan Diseases
Rare Diseases